GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (DUB:OVXA) » Definitions » EBIT

Ovoca Bio (DUB:OVXA) EBIT : €-3.99 Mil (TTM As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Ovoca Bio EBIT?

Ovoca Bio's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €-1.24 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-3.99 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ovoca Bio's annualized ROC % for the quarter that ended in Jun. 2024 was -460.48%. Ovoca Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ovoca Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 273.51%.

Ovoca Bio EBIT Historical Data

The historical data trend for Ovoca Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio EBIT Chart

Ovoca Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.88 -2.30 -5.23 -5.57 -5.10

Ovoca Bio Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.65 0.07 -2.36 -2.74 -1.24

Competitive Comparison of Ovoca Bio's EBIT

For the Biotechnology subindustry, Ovoca Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovoca Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovoca Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ovoca Bio's EV-to-EBIT falls into.


Ovoca Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-3.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovoca Bio  (DUB:OVXA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ovoca Bio's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-2.482 * ( 1 - 0% )/( (0.666 + 0.412)/ 2 )
=-2.482/0.539
=-460.48 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.468 - 0.301 - ( 3.337 - max(0, 0.967 - 3.468+3.337))
=0.666

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.101 - 0.451 - ( 2.925 - max(0, 0.863 - 3.101+2.925))
=0.412

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Ovoca Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.482/( ( (0 + max(-0.942, 0)) + (0 + max(-0.687, 0)) )/ 2 )
=-2.482/( ( 0 + 0 )/ 2 )
=-2.482/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.025) - (0.301 + 0 + 0.666)
=-0.942

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.175 + 0 + 0.0010000000000003) - (0.451 + 0 + 0.412)
=-0.687

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ovoca Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-3.985/-1.457
=273.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovoca Bio EBIT Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovoca Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (DUB:OVXA) » Definitions » EBIT
Comparable Companies
LSE:PTEC LSE:RSW LSE:FOXT LSE:HILS LSE:SLP LSE:TPFG LSE:EKF LSE:CCP LSE:ATYM LSE:HICL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
OVB.GB:UK OVB:UK OVXA:Germany
Address
17 Pembroke Street Upper, Dublin, IRL, D02 AT22
Website
https://www.ovocabio.com
Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.

Ovoca Bio Headlines

No Headlines